Patient Safety and Incentives for Continued Innovation Must be Provided in Any Pathway for the Approval of Follow-On Biologics, BIO Tells FTC – BIO

You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

Print

Read BIO's Comments to the FTC

comments10012008_0.pdf